Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 November 2005, Vol. 106, No. 10, pp. 3609-3617.
Prepublished online as a Blood First Edition Paper on August 4, 2005; DOI 10.1182/blood-2005-04-1489.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-04-1489v1
106/10/3609    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stühmer, T.
Right arrow Articles by Bargou, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stühmer, T.
Right arrow Articles by Bargou, R. C.
Related Collections
Right arrow Neoplasia
Right arrow Oncogenes and Tumor Suppressors
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma

Thorsten Stühmer, Manik Chatterjee, Martin Hildebrandt, Pia Herrmann, Hella Gollasch, Christian Gerecke, Sebastian Theurich, Luisa Cigliano, Rudolf A. Manz, Peter T. Daniel, Kurt Bommert, Lyubomir T. Vassilev, and Ralf C. Bargou

From the Department of Internal Medicine II, Division of Hematology and Oncology, University Clinics Würzburg, Würzburg, Germany; the Department of Hematology, Oncology, and Tumorimmunology, Robert Rössle Cancer Clinic at the Max Delbrück Center for Molecular Medicine, Charité-Berlin University Medicine, Campus Buch, Berlin, Germany; Discovery Oncology, Hoffmann-La Roche, Nutley, NJ; and Department of Humoral Immunology, German Rheumatism Research Center, Berlin, Germany.

Mutation of p53 is a rare event in multiple myeloma, but it is unknown if p53 signaling is functional in myeloma cells, and if targeted nongenotoxic activation of the p53 pathway is sufficient to kill tumor cells. Here, we demonstrate that treatment of primary tumor samples with a small-molecule inhibitor of the p53–murine double minute 2 (MDM2) interaction increases the level of p53 and induces p53 targets and apoptotic cell death. Significantly, given the importance of the bone marrow microenvironment for the support and drug resistance of myeloma cells, tumor cells undergo effective apoptosis also in the presence of stromal cells, which themselves appear to tolerate exposure to nutlin-3. The in vitro toxicity of nutlin-3 was similar to that of the genotoxic drug melphalan. Because nutlin-mediated p53 activation is not dependent on DNA damage, MDM2 antagonists may help to avoid or reduce the severe genotoxic side effects of chemotherapeutic agents currently used to treat multiple myeloma. Therefore, MDM2 antagonists may offer a new treatment option for this disease.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
M. Miyachi, N. Kakazu, S. Yagyu, Y. Katsumi, S. Tsubai-Shimizu, K. Kikuchi, K. Tsuchiya, T. Iehara, and H. Hosoi
Restoration of p53 Pathway by Nutlin-3 Induces Cell Cycle Arrest and Apoptosis in Human Rhabdomyosarcoma Cells
Clin. Cancer Res., June 15, 2009; 15(12): 4077 - 4084.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Secchiero, E. Melloni, M. G. di Iasio, M. Tiribelli, E. Rimondi, F. Corallini, V. Gattei, and G. Zauli
Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism
Blood, April 30, 2009; 113(18): 4300 - 4308.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. M. Ocio, P. Maiso, X. Chen, M. Garayoa, S. Alvarez-Fernandez, L. San-Segundo, D. Vilanova, L. Lopez-Corral, J. C. Montero, T. Hernandez-Iglesias, et al.
Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks
Blood, April 16, 2009; 113(16): 3781 - 3791.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
M. Wade and G. M. Wahl
Targeting Mdm2 and Mdmx in Cancer Therapy: Better Living through Medicinal Chemistry?
Mol. Cancer Res., January 1, 2009; 7(1): 1 - 11.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
D. Kranz, C. Dohmesen, and M. Dobbelstein
BRCA1 and Tip60 determine the cellular response to ultraviolet irradiation through distinct pathways
J. Cell Biol., October 23, 2008; 182(1): 197 - 213.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Zollinger, T. Stuhmer, M. Chatterjee, S. Gattenlohner, E. Haralambieva, H.-K. Muller-Hermelink, M. Andrulis, A. Greiner, C. Wesemeier, J. C. Rath, et al.
Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma
Blood, October 15, 2008; 112(8): 3403 - 3411.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Lunghi, N. Giuliani, L. Mazzera, G. Lombardi, M. Ricca, A. Corradi, A. M. Cantoni, L. Salvatore, R. Riccioni, A. Costanzo, et al.
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways
Blood, September 15, 2008; 112(6): 2450 - 2462.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. J. Jones, Q. Chen, P. M. Voorhees, K. H. Young, N. Bruey-Sedano, D. Yang, and R. Z. Orlowski
Inhibition of the p53 E3 Ligase HDM-2 Induces Apoptosis and DNA Damage-Independent p53 Phosphorylation in Mantle Cell Lymphoma
Clin. Cancer Res., September 1, 2008; 14(17): 5416 - 5425.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
N. Zhu, L. Gu, F. Li, and M. Zhou
Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells
Mol. Cancer Ther., May 1, 2008; 7(5): 1101 - 1109.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Secchiero, F. Corallini, E. Rimondi, C. Chiaruttini, M. G. di Iasio, A. Rustighi, G. Del Sal, and G. Zauli
Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells
Blood, February 1, 2008; 111(3): 1287 - 1294.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
C. F. Cheok, A. Dey, and D. P. Lane
Cyclin-Dependent Kinase Inhibitors Sensitize Tumor Cells to Nutlin-Induced Apoptosis: a Potent Drug Combination
Mol. Cancer Res., November 1, 2007; 5(11): 1133 - 1145.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. E. Kan, J. T. Patton, G. R. Stark, and M. W. Jackson
p53-Mediated Growth Suppression in Response to Nutlin-3 in Cyclin D1 Transformed Cells Occurs Independently of p21
Cancer Res., October 15, 2007; 67(20): 9862 - 9868.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. Drakos, A. Thomaides, L. J. Medeiros, J. Li, V. Leventaki, M. Konopleva, M. Andreeff, and G. Z. Rassidakis
Inhibition of p53-Murine Double Minute 2 Interaction by Nutlin-3A Stabilizes p53 and Induces Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma
Clin. Cancer Res., June 1, 2007; 13(11): 3380 - 3387.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Jiang, N. Pabla, R. F. Murphy, T. Yang, X.-M. Yin, K. Degenhardt, E. White, and Z. Dong
Nutlin-3 Protects Kidney Cells during Cisplatin Therapy by Suppressing Bax/Bak Activation
J. Biol. Chem., January 26, 2007; 282(4): 2636 - 2645.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
X. Wang and J. Robbins
Heart Failure and Protein Quality Control
Circ. Res., December 8, 2006; 99(12): 1315 - 1328.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Wade, E. T. Wong, M. Tang, J. M. Stommel, and G. M. Wahl
Hdmx Modulates the Outcome of P53 Activation in Human Tumor Cells
J. Biol. Chem., November 3, 2006; 281(44): 33036 - 33044.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Van Maerken, F. Speleman, J. Vermeulen, I. Lambertz, S. De Clercq, E. De Smet, N. Yigit, V. Coppens, J. Philippe, A. De Paepe, et al.
Small-Molecule MDM2 Antagonists as a New Therapy Concept for Neuroblastoma
Cancer Res., October 1, 2006; 66(19): 9646 - 9655.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
E. Barbieri, P. Mehta, Z. Chen, L. Zhang, A. Slack, S. Berg, and J. M. Shohet
MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death.
Mol. Cancer Ther., September 1, 2006; 5(9): 2358 - 2365.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Kojima, M. Konopleva, T. McQueen, S. O'Brien, W. Plunkett, and M. Andreeff
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia
Blood, August 1, 2006; 108(3): 993 - 1000.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
N. E. Kay
p53 activation comes to the rescue in CLL
Blood, May 15, 2006; 107(10): 3815 - 3816.
[Full Text] [PDF]


Home page
BloodHome page
P. Secchiero, E. Barbarotto, M. Tiribelli, C. Zerbinati, M. G. di Iasio, A. Gonelli, F. Cavazzini, D. Campioni, R. Fanin, A. Cuneo, et al.
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL)
Blood, May 15, 2006; 107(10): 4122 - 4129.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. T. Patton, L. D. Mayo, A. D. Singhi, A. V. Gudkov, G. R. Stark, and M. W. Jackson
Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3.
Cancer Res., March 15, 2006; 66(6): 3169 - 3176.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020